CN101835793B - 抑制β1-肾上腺素受体抗体的突变双环化受体肽 - Google Patents

抑制β1-肾上腺素受体抗体的突变双环化受体肽 Download PDF

Info

Publication number
CN101835793B
CN101835793B CN200880112623.0A CN200880112623A CN101835793B CN 101835793 B CN101835793 B CN 101835793B CN 200880112623 A CN200880112623 A CN 200880112623A CN 101835793 B CN101835793 B CN 101835793B
Authority
CN
China
Prior art keywords
cyclic peptide
cys
peptide
halfcystine
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880112623.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN101835793A (zh
Inventor
罗兰·耶恩斯
瓦勒瑞·耶恩斯
马丁·罗瑟
维亚彻斯拉韦·尼科莱维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of CN101835793A publication Critical patent/CN101835793A/zh
Application granted granted Critical
Publication of CN101835793B publication Critical patent/CN101835793B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
CN200880112623.0A 2007-08-24 2008-08-22 抑制β1-肾上腺素受体抗体的突变双环化受体肽 Expired - Fee Related CN101835793B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07016637.6 2007-08-24
EP07016637 2007-08-24
PCT/EP2008/006932 WO2009027063A2 (en) 2007-08-24 2008-08-22 MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING β1-ADRENOCEPTOR ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410108364.1A Division CN103992406A (zh) 2007-08-24 2008-08-22 抑制β1-肾上腺素受体抗体的突变双环化受体肽

Publications (2)

Publication Number Publication Date
CN101835793A CN101835793A (zh) 2010-09-15
CN101835793B true CN101835793B (zh) 2014-04-23

Family

ID=40130559

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880112623.0A Expired - Fee Related CN101835793B (zh) 2007-08-24 2008-08-22 抑制β1-肾上腺素受体抗体的突变双环化受体肽
CN201410108364.1A Pending CN103992406A (zh) 2007-08-24 2008-08-22 抑制β1-肾上腺素受体抗体的突变双环化受体肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410108364.1A Pending CN103992406A (zh) 2007-08-24 2008-08-22 抑制β1-肾上腺素受体抗体的突变双环化受体肽

Country Status (13)

Country Link
US (1) US9062095B2 (enExample)
EP (3) EP2559698B1 (enExample)
JP (3) JP5248610B2 (enExample)
CN (2) CN101835793B (enExample)
AU (1) AU2008291296B2 (enExample)
CA (1) CA2697108C (enExample)
DK (1) DK2197900T3 (enExample)
ES (1) ES2391358T3 (enExample)
HR (1) HRP20120827T1 (enExample)
PL (1) PL2197900T3 (enExample)
PT (1) PT2197900E (enExample)
SI (1) SI2197900T1 (enExample)
WO (1) WO2009027063A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027063A2 (en) * 2007-08-24 2009-03-05 Julius-Maximilians-Universität Würzburg MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING β1-ADRENOCEPTOR ANTIBODIES
BRPI1007007A2 (pt) * 2009-01-27 2016-03-22 Julius Maximilians Universität Würzburg peptídeos cíclico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção de um peptídeo cíclico, composição farmacêutica, método para detecção de anticorpos contra um b-ar (em uma amostra)
DE102010018878B4 (de) 2009-04-30 2013-09-26 Julius-Maximilians-Universität Würzburg Neue Zell-Linie zur Fluoreszenz-basierten Detektion von funktionell aktiven Antikörpern und Autoantikörpern gegen den Beta1-adrenergen Rezeptor
EP2402016A1 (en) * 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
JP2014519329A (ja) 2011-06-10 2014-08-14 コリムン ゲーエムベーハー ヒトβ１−アドレノレセプター（β１−ＡＲ）に対する結合化合物および自己−抗β１−ＡＲ抗体の測定におけるその使用
JP6170077B2 (ja) 2012-02-16 2017-07-26 エータイアー ファーマ， インコーポレイテッド 自己免疫および炎症疾患を処置するためのヒスチジルｔＲＮＡ合成酵素
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
WO2015022953A1 (ja) * 2013-08-14 2015-02-19 株式会社新日本科学 血液脳関門障害改善剤
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
CN108218963B (zh) * 2018-01-19 2020-10-13 首都医科大学 一种环肽及其制备方法和用途
CA3130446A1 (en) * 2019-03-14 2020-09-17 Genentech, Inc. Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
KR20230074641A (ko) * 2020-09-23 2023-05-30 아블레비아 바이오테크 게엠베하 자가항체-매개 병태의 예방 또는 치료를 위한 화합물
CN112266330B (zh) * 2020-10-15 2023-02-24 长沙博源医疗科技有限公司 一种甲氧基肾上腺素衍生物、免疫原、抗甲氧基肾上腺素特异性抗体及其制备方法与应用
EP4392430A1 (en) * 2021-08-27 2024-07-03 Yale University Molecular degraders of extracellular proteins
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1433325A (zh) * 1999-11-05 2003-07-30 加利福尼亚大学董事会 通过体内基因递送治疗心血管疾病的技术和组合物
WO2006103101A2 (en) * 2005-03-31 2006-10-05 Julius-Maximilians-Universität Würzburg MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
CN1988914A (zh) * 2001-08-23 2007-06-27 西兰制药公司 胞间通讯易化化合物的新医学用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
JP2003514772A (ja) * 1999-09-21 2003-04-22 アフィーナ イミュンテヒニク ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｃｍを引き起こす自己抗体に対するペプチド
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP4541490B2 (ja) * 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
WO2001083693A2 (en) * 2000-04-28 2001-11-08 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
JP2005521733A (ja) * 2002-03-26 2005-07-21 ダイアックス、コープ フィブリノーゲン結合部分
US20080206264A1 (en) * 2003-02-04 2008-08-28 New York University Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists
EP1536020A1 (en) 2003-11-26 2005-06-01 Bayerische Julius-Maximilians-Universität Würzburg Means and methods for optical determination of cAMP in vitro and in vivo
WO2009027063A2 (en) * 2007-08-24 2009-03-05 Julius-Maximilians-Universität Würzburg MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING β1-ADRENOCEPTOR ANTIBODIES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1433325A (zh) * 1999-11-05 2003-07-30 加利福尼亚大学董事会 通过体内基因递送治疗心血管疾病的技术和组合物
CN1988914A (zh) * 2001-08-23 2007-06-27 西兰制药公司 胞间通讯易化化合物的新医学用途
WO2006103101A2 (en) * 2005-03-31 2006-10-05 Julius-Maximilians-Universität Würzburg MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES

Also Published As

Publication number Publication date
CN101835793A (zh) 2010-09-15
EP2559698A2 (en) 2013-02-20
EP2559698A3 (en) 2013-03-06
EP2197900B1 (en) 2012-08-01
AU2008291296B2 (en) 2014-02-06
US9062095B2 (en) 2015-06-23
PL2197900T3 (pl) 2012-12-31
HK1176363A1 (en) 2013-07-26
EP2559698B1 (en) 2014-11-12
ES2391358T3 (es) 2012-11-23
HRP20120827T1 (hr) 2012-11-30
EP2197900A2 (en) 2010-06-23
JP2010536356A (ja) 2010-12-02
WO2009027063A3 (en) 2009-07-23
JP5248610B2 (ja) 2013-07-31
CN103992406A (zh) 2014-08-20
EP2497777A2 (en) 2012-09-12
JP2013138679A (ja) 2013-07-18
EP2197900B9 (en) 2013-01-09
SI2197900T1 (sl) 2012-11-30
AU2008291296A1 (en) 2009-03-05
US20100209445A1 (en) 2010-08-19
EP2497777A3 (en) 2012-10-10
CA2697108C (en) 2018-05-22
PT2197900E (pt) 2012-10-24
WO2009027063A2 (en) 2009-03-05
DK2197900T3 (da) 2012-10-22
CA2697108A1 (en) 2009-03-05
JP2013176369A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
CN101835793B (zh) 抑制β1-肾上腺素受体抗体的突变双环化受体肽
JP5788430B2 (ja) 抗β１アドレナリン受容体抗体を阻害する手段
US20040047880A1 (en) Component for vaccine
ZA200309126B (en) Recombinant antibodies against infectious bursal disease virus (IBDV).
EP2391637A1 (en) Novel peptide-homologues for inhibiting beta1-adrenoceptor antibodies
JP4855261B2 (ja) 抗ヒストンｈ１モノクローナル抗体およびこれを産生するハイブリドーマ
Böttger et al. Identification of peptide mimotopes for the fluorescein hapten binding of monoclonal antibody B13‐DE1
Weiner et al. Biological approaches to rational drug design
US20150038673A1 (en) Mutant double cyclized receptor peptides inhibiting beta1-adrenoceptor antibodies
AU2013205476A1 (en) Mutant double cyclized receptor peptides inhibiting beta1-adrenoceptor antibodies
WO2005095609A1 (ja) 心機能抑制／降圧性新規内因性生理活性ペプチド
HK1176363B (en) Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies
HK1174048A (en) Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies
Robles et al. Isolation of the Taenia crassiceps antigens from a phage display cDNA library and evaluation of their use for diagnosis of neurocysticercosis
US20070249531A1 (en) Method for the Detection of Autoantibodies Against Specific Peptides and Its Use in Diagnosis and Treatment of Pregnancy-Loss or Infertility

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140423